ATR and ovarian cancer: CAPRI is a phase II clinical trial of olaparib in combination with the ATR inhibitor ceralasertib (AZD6738) in patients with recurrent ovarian cancer; data on the platinum-resistant ovarian cancer cohort of this trial has been published[49].